Effects of the enteral administration of Bifidobacterium breve on patients undergoing chemotherapy for pediatric malignancies

Wada, Mariko; Nagata, Satoru; Saito, Masahiro; Shimizu, Toshiaki; Yamashiro, Yuichiro; Matsuki, Takahiro; Asahara, Takashi; Nomoto, Koji

doi:10.1007/s00520-009-0711-6

Cited by 127 publications

(100 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…32 34 50–52 54–58 The type of enrolled participants varied from healthy volunteers to children with untreated respiratory infections, to paediatric cancer patients. For participants with acute infections or cancer, baseline assays were performed prior to the disrupting agent (antibiotics or chemotherapy).…”

Section: Resultsmentioning

confidence: 99%

“…The mixture of L. acidophilus and B. longum did not show any changes in the microbiota. Wada et al 32 claimed B. breve ‘enhanced intestinal anaerobes’, but this was only compared to the placebo group. Their data showed chemotherapy is a disruptive event, resulting in more enterobacteria in the intestine in the placebo group, but there were no significant differences seen by the end of the 8 weeks follow-up in either the probiotic or the placebo group compared to baseline microbiota levels.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Use of probiotics to correct dysbiosis of normal microbiota following disease or disruptive events: a systematic review

2014

View full text Add to dashboard Cite

ObjectiveTo assess the evidence for the claim probiotics can correct dysbiosis of the normal microbiota resulting from disease or disruptive events.SettingSystematic review of published clinical trials of patients receiving a probiotic intervention for the prevention or treatment of various diseases.Data sourcesSources searched (1985–2013): PubMed, EMBASE, Cochrane Database of Systematic Reviews, CINAHL, AMED and ISI Web of Science. Three on-line clinical trial registries were searched: Cochrane Central Register of Controlled trials, MetaRegister of Controlled Trials and National Institutes of Health.Review methodsIncluded studies were randomised clinical trials of probiotic interventions having microbiological assays. Studies were evaluated following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines for specific probiotic strains. A standard data extraction form was used to collect the raw data.Outcome measuresThe primary outcome is the degree of microbiota correction by specific probiotic strains. Secondary outcome was the association between the degree of dysbiosis correction and clinical efficacy.ResultsThe review of the literature found three distinct study designs: model A (restoration) assayed patients enrolled with a healthy, undisturbed microbiota and then assayed postdisruptive event and probiotic therapy; model B (alteration) assayed patients with pre-existing disrupted microbiota and then postprobiotic therapy; model C (no dysbiosis) assayed volunteers with no disruptive event prebiotic and postprobiotic. From a total of 63 trials, 83% of the probiotic products using model A restored the microbiota, 56% using model B improved the microbiota and only 21% using model C had any effect on microbiota. Clinical efficacy was more commonly associated with strains capable of restoration of the normal microbiota.ConclusionsThe ability to assess the degree of dysbiosis improvement is dependent on the enrolled population and the timing of microbiological assays. The functional claim for correcting dysbiosis is poorly supported for most probiotic strains and requires further research.Trial registration numberPROSPERO (CRD42014007224).

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Use of probiotics to correct dysbiosis of normal microbiota following disease or disruptive events: a systematic review

2014

View full text Add to dashboard Cite

show abstract

“…These young patients suffered from infectious complications; after probiotic administration, the use of antibiotics to cure infections was lower and the gut habitation of anaerobes was enhanced. 16 In hospitalized children, the administration of L. reuteri DSM 17938 compared with placebo had no effect on the overall incidence of nosocomial diarrhea, including rotavirus infection. 17 Treatment This is the main indication for probiotics in childhood and has been discussed in several documents on the basis of a large mass of data.…”

Section: Hospital-acquired Diarrheamentioning

confidence: 99%

Probiotics for Prevention and Treatment of Diarrhea

Guarino

Guandalini

Vecchio

2015

Journal of Clinical Gastroenterology

157

View full text Add to dashboard Cite

Probiotics are increasingly used for prevention and treatment of diarrhea more in children than in adults. Given the broad spectrum of diarrhea, this review focuses on the main etiologies: acute gastroenteritis, antibiotic-associated diarrhea (AAD), and necrotizing enterocolitis (NEC). For each, we reviewed randomized controlled trials, meta-analyses, and guidelines. For acute gastroenteritis we found 12 guidelines: 5 recommended probiotics and 7 did not. However, the guidelines containing positive recommendations provided proof of evidence from clinical trials and meta-analyses. Lactobacillus rhamnosus GG (LGG) and Saccharomyces boulardii had the most compelling evidence of efficacy as they reduced the duration of the disease by 1 day. For AAD 4 meta-analyses were found, reporting variable efficacy of probiotics in preventing diarrhea, based on the setting, patient's age, and antibiotics. The most effective strains were LGG and S. boulardii. For NEC, we found 3 randomized controlled trials, 5 meta-analyses, and 4 position papers. Probiotics reduced the risk of NEC enterocolitis and mortality in preterm babies. Guidelines did not support a routine use of probiotics and asked for further data for such sensitive implications. In conclusion, there is strong and solid proof of efficacy of probiotics as active treatment of gastroenteritis in addition to rehydration. There is solid evidence that probiotics have some efficacy in prevention of AAD, but the number needed to treat is an issue. For both etiologies LGG and S. boulardii have the strongest evidence. In NEC the indications are more debated, yet on the basis of available data and their implications, probiotics should be carefully considered.

show abstract

“…A second study [18] evaluated the administration of Bifidobacterium longum CECT 7347 in children on a GFD with newly diagnosed CD and it revealed a reduction of CD3+ T lymphocytes and TNF-α due to probiotic ingestion. To date, no studies on CD considered the administration of Bifidobacterium breve strains although this species has proven very successful in several paediatric trials regarding necrotizing enterocolitis, immunodeficiency and constipation [19,20,21]. …”

Section: Introductionmentioning

confidence: 99%

Effect of Bifidobacterium breve on the Intestinal Microbiota of Coeliac Children on a Gluten Free Diet: A Pilot Study

et al. 2016

View full text Add to dashboard Cite

Coeliac disease (CD) is associated with alterations of the intestinal microbiota. Although several Bifidobacterium strains showed anti-inflammatory activity and prevention of toxic gliadin peptides generation in vitro, few data are available on their efficacy when administered to CD subjects. This study evaluated the effect of administration for three months of a food supplement based on two Bifidobacterium breve strains (B632 and BR03) to restore the gut microbial balance in coeliac children on a gluten free diet (GFD). Microbial DNA was extracted from faeces of 40 coeliac children before and after probiotic or placebo administration and 16 healthy children (Control group). Sequencing of the amplified V3-V4 hypervariable region of 16S rRNA gene as well as qPCR of Bidobacterium spp., Lactobacillus spp., Bacteroides fragilis group Clostridium sensu stricto and enterobacteria were performed. The comparison between CD subjects and Control group revealed an alteration in the intestinal microbial composition of coeliacs mainly characterized by a reduction of the Firmicutes/Bacteroidetes ratio, of Actinobacteria and Euryarchaeota. Regarding the effects of the probiotic, an increase of Actinobacteria was found as well as a re-establishment of the physiological Firmicutes/Bacteroidetes ratio. Therefore, a three-month administration of B. breve strains helps in restoring the healthy percentage of main microbial components.

show abstract

Effects of the enteral administration of Bifidobacterium breve on patients undergoing chemotherapy for pediatric malignancies

Abstract: These data, although based on a limited number of patients and samples, suggest that administration of B. breve strain Yakult could be an effective approach for achieving clinical benefits in immunocompromised hosts by improving their intestinal environments.

Cited by 127 publications

References 33 publications

Use of probiotics to correct dysbiosis of normal microbiota following disease or disruptive events: a systematic review

Use of probiotics to correct dysbiosis of normal microbiota following disease or disruptive events: a systematic review

Probiotics for Prevention and Treatment of Diarrhea

Effect of Bifidobacterium breve on the Intestinal Microbiota of Coeliac Children on a Gluten Free Diet: A Pilot Study

Contact Info

Product

Resources

About